Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | EEF2K | O00418 | 3/20 | 0.37 |
| ▸ | CTSA | P10619 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3453796 | 0.83 | DPP4 (0.37) | AAK1LTA4H | |
| SCHEMBL6246072 | 0.82 | CYP2C19 (0.39) | AAK1EEF2KCTSAMEN1KMT2A | |
| SCHEMBL1519634 | 0.80 | APP (0.44) | MEN1KMT2ACYP2C19GAA | |
| SCHEMBL1519829 | 0.79 | FFAR1 (0.40) | AAK1MEN1KMT2ACYP2C19CTSS | |
| SCHEMBL27506659 | 0.76 | IDO1 (0.39) | AAK1MEN1KMT2ACTSSCTSK | |
| SCHEMBL27477423 | 0.76 | IDO1 (0.39) | AAK1MEN1KMT2ACTSSCTSK | |
| SCHEMBL1521461 | 0.75 | LMNA (0.40) | EEF2KCTSACYP2C19IDO1GAA | |
| SCHEMBL1519893 | 0.75 | FFAR1 (0.39) | CYP2C19 | |
| SCHEMBL1519753 | 0.74 | FFAR1 (0.44) | EEF2K | |
| SCHEMBL15268637 | 0.74 | ROCK2 (0.40) | AAK1MEN1KMT2ACTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275086-A1 | Dpp-Iv Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2008-11-06 | — | — | US | disclosed |
| EP-1858846-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2007-11-28 | — | — | EP | disclosed |
| US-20070265301-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| EP-1828138-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| CN-1980892-A | Dpp-IV inhibitors | SANTHERA PHARMACEUTICALS CH (CH) | 2007-06-13 | — | — | CN | disclosed |
| EP-1758861-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006097175-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| EP-1702916-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Schweiz) GmbH (CH) | 2006-09-20 | — | — | EP | disclosed |
| EP-1604989-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005113510-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-01 | — | — | WO | disclosed |
| EP-1598341-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005095343-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005056013-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
| EP-1541148-A1 | DPP-IV INHIBITORS | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | AAK1 4059/4885EEF2K 4035/4885CTSA 1434/4885 |
| US-20080275086-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | AAK1 3326/4885EEF2K 3428/4885CTSA 1501/4885 |
| US-20070265301-A1 | Dpp-IV Inhibitors | DPP4, DPP8, DPP7 | AAK1 2369/4885EEF2K 4354/4885CTSA 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.